Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences

Core Insights - Codexis, Inc. has entered into a non-exclusive commercial and manufacturing license agreement with Alphazyme LLC for multiple enzymes in its life science enzyme portfolio, including HiFi DNA Polymerase and HiTemp Reverse Transcriptase [1][3] - The agreement allows Codexis to receive sales-based royalties and is part of its strategy to divest non-core assets while focusing on its Pharmaceutical Manufacturing business and ECO Synthesis™ platform [3][4] Company Strategy - The partnership with Alphazyme is expected to enhance Codexis' commercial reach in the genomics segment, leveraging Alphazyme's existing sales force and experience [2][3] - Codexis aims to maintain focus on maximizing near-term commercial opportunities, including the growth of its Pharmaceutical Manufacturing business and the build-out of its ECO Synthesis™ Innovation Lab [2][3] Product Development - Codexis is developing its proprietary ECO Synthesis™ manufacturing platform to enable the commercial-scale manufacture of RNAi therapeutics through an enzymatic route, addressing scalability and cost limitations of traditional methods [5] - Recent data presented at TIDES USA 2024 demonstrated that Codexis achieved coupling efficiency greater than 98% in enzymatic synthesis, comparable to traditional phosphoramidite chemistry [5] Industry Context - Alphazyme is recognized as a premier partner for industrial-scale molecular biology enzymes, collaborating with manufacturers in the nucleic acid synthesis and detection markets [2][6] - Maravai LifeSciences, the parent company of Alphazyme, provides critical products for drug therapies, diagnostics, and vaccines, positioning itself as a leader in the life sciences sector [7]